Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2017

01-08-2017 | Editorial

Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained

Authors: Elif Hindié, Charles Mesguich, Krimo Bouabdallah, Noël Milpied

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2017

Login to get access

Excerpt

Positron emission tomography with 18F–fluorodeoxyglucose (FDG-PET) has become a cornerstone procedure in the modern management of Hodgkin’s lymphoma (HL) [1‐4]. It offers better initial staging and risk stratification [3]. FDG-PET often detects occult extranodal disease, notably focal bone marrow lesions [5‐7]. It rendered useless routine bone marrow biopsy [3]. HL is associated with a high rate of residual masses at the end of therapy, which are difficult to characterize as residual disease or not on conventional imaging. Therefore, a major milestone was the finding that end-of-treatment FDG-PET offers excellent prediction of progression-free-survival (PFS), even in the presence of a residual mass [8‐11]. This finding led to the introduction of FDG-PET imaging in response criteria for HL [12]. …
Literature
1.
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–8.CrossRefPubMed
2.
Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:434–42.CrossRefPubMed
3.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefPubMedPubMedCentral
4.
Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M, et al. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii70–5.CrossRefPubMed
5.
Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.CrossRefPubMed
6.
El-Galaly TC, d’Amore F, Mylam KJ, de Nully BP, Bogsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14.CrossRefPubMed
7.
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood. 2016;127:1531–8.CrossRefPubMed
8.
Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272–8.CrossRefPubMed
9.
Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930–4.CrossRefPubMed
10.
Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: a systematic review. J Nucl Med. 2008;49:13–21.CrossRefPubMed
11.
Adams HJ, Nievelstein RA, Kwee TC. Outcome of Hodgkin lymphoma patients with a posttreatment (18)F-Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET)-negative residual mass: systematic review and meta-analysis. Pediatr Hematol Oncol. 2015;32:515–24.CrossRefPubMed
12.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed
13.
Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest Oncology group S0816. J Clin Oncol. 2016;34:2020–7.CrossRefPubMedPubMedCentral
14.
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–29.CrossRefPubMedPubMedCentral
15.
16.
Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13.CrossRefPubMedPubMedCentral
17.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34:1175–81.CrossRefPubMed
18.
Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol. 2016;53:186–9.CrossRefPubMed
19.
Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.CrossRefPubMed
20.
Strobel K, Schaefer NG, Renner C, Veit-Haibach P, Husarik D, Koma AY, et al. Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658–64.CrossRefPubMed
21.
Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4–12.CrossRefPubMed
22.
Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175:652–60.
23.
Fanti S, Castellucci P, Stefoni V, Nanni C, Tani M, Rubello D, et al. Early relapse in a patient with Hodgkin’s disease and negative interim FDG-PET. Ann Nucl Med. 2008;22:429–32.CrossRefPubMed
24.
Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34:1376–85.CrossRefPubMed
25.
Casasnovas O, Kanoun S, Tal I, Cottereau AS, Edeline V, Brice P, et al. Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. J Clin Oncol. 2016;34.
26.
Cuccaro A, Annunziata S, Cupelli E, Martini M, Calcagni ML, Rufini V, et al. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Med. 2016;5:398–406.CrossRefPubMedPubMedCentral
27.
Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol. 2016;3:e467–e79.CrossRefPubMed
28.
Bari A, Marcheselli L, Marcheselli R, Pozzi S, Cox MC, Baldessari C, et al. Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients. Br J Haematol. 2016. doi:10.​1111/​bjh.​14406.
29.
Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, et al. Non-invasive detection of genomic imbalances in Hodgkin/reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2015;2:e55–65.CrossRefPubMed
30.
Ganeshan B, Miles KA, Babikir S, Shortman R, Afaq A, Ardeshna KM, et al. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas. Eur Radiol. 2017;27:1012–20.CrossRefPubMed
31.
Hatt M, Majdoub M, Vallieres M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44.CrossRefPubMed
32.
Lartizien C, Rogez M, Niaf E, Ricard F. Computer-aided staging of lymphoma patients with FDG PET/CT imaging based on textural information. IEEE J Biomed Health Inform. 2014;18:946–55.CrossRefPubMed
33.
Scott DW, Steidl C. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. Hematology Am Soc Hematol Educ Program. 2014;2014:144–50.PubMed
Metadata
Title
Advanced Hodgkin’s lymphoma: End-of-treatment FDG-PET should be maintained
Authors
Elif Hindié
Charles Mesguich
Krimo Bouabdallah
Noël Milpied
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3714-4

Other articles of this Issue 8/2017

European Journal of Nuclear Medicine and Molecular Imaging 8/2017 Go to the issue

Book Review

Valentina Ambrosini and Stefano Fanti (eds): Clinicians’ Guides to Radionuclide Hybrid Imaging: PET/CT in Neuroendocrine Tumors

Original Article

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas

Original Article

Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden

Review Article

Accuracy of diagnostic imaging modalities for peripheral post-traumatic osteomyelitis – a systematic review of the recent literature

Original Article

Comparison of CT and PET/CT for biopsy guidance in oncological patients

Original Article

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients